Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 3Depression 2Anxiety Disorders 2Urinary Incontinence 1Sleep Initiation and Maintenance Disorders 1Postoperative Complications 1Pain 1PGS 1Neoplasms 1Fatigue 1Colorectal Neoplasms 1Cancer Pain 1Breast Neoplasms 1

Interventions

Exercise 8Standard of Care 5trametinib 3tislelizumab 3Radiotherapy 3Radiosurgery 3Palliative Care 3Paclitaxel 3Gemcitabine 3130-nm albumin-bound paclitaxel 3trastuzumab deruxtecan 2cemiplimab 2Therapeutics 2Surveys and Questionnaires 2Resistance Training 2Oxaliplatin 2Nivolumab 2Maintenance 2Immune Checkpoint Inhibitors 2Drug Therapy 2Cisplatin 2Carboplatin 2vedolizumab 1toripalimab 1surufatinib 1sparsentan 1sintilimab 1semaglutide 1posaconazole 1pomalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Neoplasms × Electroacupuncture × Clear all
NCT06891521 2025-03-24

Electroacupuncture for Preventing Adverse Events of Cancer Immunotherapy

Qinghai Red Cross Hospital

Phase 2 Not yet recruiting
123 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡